Narendra Wagle
Affiliations: | University of Toronto, Toronto, ON, Canada |
Area:
History of Religion, BiographyGoogle:
"Narendra Wagle"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Wander SA, Cohen O, Gong X, et al. (2020) Abstract PD2-09: The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in patients with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC) Cancer Research. 80 |
| Wander S, Mao P, Lloyd M, et al. (2020) Abstract P6-10-08: AKT1 alterations following exposure to endocrine-based therapy in patients with hormone-receptor positive (HR+) metastatic breast cancer (MBC): Clinical and functional implications Cancer Research. 80 |
| Nayar U, Piccioni F, Yang X, et al. (2020) Abstract 1914: Phenotypic characterization of a comprehensive set of HER2 missense mutants in ER+ breast cancer Cancer Research. 80: 1914-1914 |
| Jain E, Kim D, Buendia J, et al. (2019) Abstract PD9-03: The genomic landscape of de novo metastatic breast cancer (MBC) Cancer Research. 79 |
| Stover DG, Parsons HA, Ha G, et al. (2018) Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017760033 |
| Mo SS, Liu D, Gray SW, et al. (2018) Abstract 3254: Dissecting genomic determinants of response to platinum-based chemotherapy in advanced NSCLC and colorectal cancer Cancer Research. 78: 3254-3254 |
| Giltnane JM, Hutchinson KE, Stricker TP, et al. (2017) Genomic profiling of ER(+) breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. Science Translational Medicine. 9 |
| Cohen O, Kim D, Oh C, et al. (2017) Abstract S1-01: Whole exome and transcriptome sequencing of resistant ER+ metastatic breast cancer Cancer Research. 77 |
| Nayar U, Cohen O, Oh C, et al. (2017) Abstract P3-04-08: The role of HER2 mutations in resistance to endocrine therapy in ER+ breast cancer Cancer Research. 77 |
| Wagle N, Painter C, Ilzarbe M, et al. (2016) Abstract OT2-05-03: The metastatic breast cancer project: A national direct-to-patient research initiative to accelerate genomics research Cancer Research. 76 |